natgillin/translations-raw huggingface dataset:
cell count cells/mm3 (S.E.M.c)
stanica/mm3 (S.E.M.c)
Cell growth: Treatment with somatropin results in an increase in both the number and size of skeletal muscle cells.
Rast stanica: Liječenje somatropinom rezultira u porastu i broja i veličine stanica poprečnoprugastih mišića.
Cell suspension: Store and transport frozen in liquid nitrogen (–196 °C).
Stanična suspenzija: čuvati i transportirati zamrznuto u tekućem dušiku (–196 °C).
Cell-associated live recombinant turkey herpes virus (rHVT/ND) expressing the fusion protein of Newcastle diseases virus D-26 lentogenic strain: 2,500 – 8,000 PFU*
Stanično vezani živi rekombinantni herpesvirus purana (rHVT/ND) izražen kao fuzijski protein lentogenog soja virusa D-26 newcastleske bolesti: 2.500 – 8.000 PFU
Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus: 103.1 – 104.1 PFU1.
Živi rekombinirani, stanično vezan herpesvirus pura (soj HVT/ILT -138), koji izražava glikoproteine gD i gI virusa zaraznog laringotraheitisa: 103,1 – 104,1 PFU1.
Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus: 103.1 – 104.1 PFU1.
Živi rekombinirani, stanično vezan herpesvirus pura soj HVT/ILT -138), koji izražava glikoproteine gD i gI virusa zaraznog laringotraheitisa: 103,1 – 104,1 PFU1.
Cell-associated live recombinant viral turkey herpes virus (rHVT/ND)
Stanično vezani živi rekombinantni herpesvirus purana (rHVT/ND)
CellCelpt contains sorbitol (a type of sugar).
CellCept sadrži sorbitol (jednu vrstu šećera).
CellCept 1 g/5 ml powder for oral suspension
CellCept 1 g/5 ml prašak za oralnu suspenziju mofetilmikofenolat
CellCept 1 g/5 ml powder for oral suspension sorbitol
CellCept 1 g/5 ml prašak za oralnu suspenziju sorbitol
CellCept 1 g/5 ml powder for oral suspension.
CellCept 1 g/5 ml prašak za oralnu suspenziju.
CellCept 1 g/5 ml powder for oral suspension:
CellCept 1 g/5 ml prašak za pripremu oralne suspenzije:
CellCept 250 mg capsules
CellCept 250 mg kapsule mofetilmikofenolat
CellCept 250 mg capsules.
CellCept 250 mg kapsule.
CellCept 250 mg capsules: 1 carton contains 100 capsules (in blister packs of 10)
CellCept kapsule 250 mg: 1 kutija sadrži 100 kapsula (u blister pakiranjima od 10 kapsula)
CellCept 500 mg film-coated tablets
CellCept 500 mg filmom obložene tablete mofetilmikofenolat
CellCept 500 mg film-coated tablets
CellCept 500 mg filmom obložene tablete:
CellCept 500 mg film-coated tablets Mycophenolate mofetil
CellCept 500 mg filmom obložene tablete mofetilmikofenolat
CellCept 500 mg film-coated tablets.
CellCept 500 mg filmom obložene tablete.
CellCept 500 mg powder for concentrate for solution for infusion
CellCept 500 mg prašak za koncentrat za otopinu za infuziju mofetilmikofenolat
CellCept 500 mg powder for concentrate for solution for infusion does not contain an antibacterial preservative; therefore, reconstitution and dilution of the product must be performed under aseptic conditions.
CellCept 500 mg prašak za koncentrat za otopinu za infuziju ne sadrži antibakterijske konzervanse te se stoga lijek mora otopiti i razrijediti u aseptičnim uvjetima.
CellCept 500 mg powder for concentrate for solution for infusion.
CellCept 500 mg prašak za koncentrat za otopinu za infuziju.
CellCept 500 mg tablets Mycophenolate mofetil
CellCept 500 mg tablete mofetilmikofenolat
CellCept capsules are oblong shaped with one end blue and the other end brown.
CellCept kapsule su duguljaste s jednim plavim i jednim smeđim krajem.
CellCept capsules should be handled with care
CellCept kapsulama rukujte oprezno
CellCept capsules should only be prescribed to patients with a body surface area of at least 1.25 m2.
CellCept kapsule smiju se propisivati samo bolesnicima tjelesne površine od najmanje 1,25 m2.
CellCept contains aspartame.
CellCept sadrži aspartam.
CellCept film-coated tablets should be handled with care Do not crush the tablets
CellCept filmom obloženim tabletama rukujte oprezno Tablete ne lomite
CellCept is contraindicated in women of childbearing potential who are not using highly effective contraception.
CellCept je kontraindiciran kod žena reproduktivne dobi koje ne koriste visoko učinkovite metode kontracepcije.
CellCept is not likely to affect you being able to drive or use any tools or machines.
Nije vjerojatno da CellCept utječe na Vašu sposobnost upravljanja motornim vozilima ili korištenja ikakvih alata ili strojeva.
Cellcept is provided in a 20 mL type I clear glass vial with a grey butyl rubber stopper and aluminium seal with a plastic flip-off cap.
CellCept se nalazi u staklenim bočicama od 20 ml bezbojnog stakla tipa I sa sivim butilnim gumenim čepom i aluminijskim prstenom s plastičnim poklopcem.
CellCept is used to prevent your body rejecting a transplanted organ.
CellCept se koristi kako bi se spriječilo da tijelo odbaci presađeni organ:
CellCept reduces your body’s defences.
CellCept oslabljuje obranu Vašeg tijela.
CellCept should not be given to patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients listed in section 6.1. Hypersensitivity reactions to CellCept have been observed (see section 4.8).
CellCept se ne smije davati bolesnicima s preosjetljivošću na mofetilmikofenolat, mikofenolatnu kiselinu ili neku od pomoćnih tvari navedenih u dijelu 6.1. Primijećene su reakcije preosjetljivosti na CellCept (vidjeti dio 4.8).
CellCept should not be given to women of childbearing potential who are not using highly effective contraception (see section 4.6).
CellCept se ne smije davati ženama reproduktivne dobi koje ne koriste visoko učinkovite metode kontracepcije (vidjeti dio 4.6).
CellCept should not be given to women who are breastfeeding (see section 4.6).
CellCept se ne smije davati dojiljama (vidjeti dio 4.6).
CellCept should not be used during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection (see section 4.6).
CellCept se ne smije koristiti u trudnoći, osim ako ne postoji prikladno alternativno liječenje kojim bi se spriječilo odbacivanje presatka (vidjeti dio 4.6).
CellCept should not be used in pregnancy unless there is no suitable alternative treatment to prevent transplant rejection (see section 4.6).
CellCept se ne smije koristiti u trudnoći, osim ako ne postoji prikladno alternativno liječenje kojim bi se spriječilo odbacivanje presatka (vidjeti dio 4.6).
CellCept should not to be used in pregnancy unless there is no suitable alternative treatment to prevent transplant rejection (see section 4.6).
CellCept se ne smije koristiti u trudnoći, osim ako ne postoji prikladno alternativno liječenje kojim bi se spriječilo odbacivanje presatka (vidjeti dio 4.6).
CellCept tablets are lavender coloured and caplet shaped.
CellCept tablete su ovalnog oblika i boje lavande.
CellCept tablets: microcrystalline cellulose, polyvidone (K-90), croscarmellose sodium, magnesium stearate tablet coating: hydroxypropyl methycellulose, hydroxypropyl cellulose, titanium dioxide (E171), polyethylene glycol 400, indigo carmine aluminium lake (E132), red iron oxide (E172).
CellCept tablete: celuloza, mikrokristalična, polividon (K-90), karmelozanatrij, umrežen, magnezijev stearat ovojnica tablete: hipromeloza, hidroksipropilceluloza, titanijev dioksid (E171), polietilenglikol 400, boja indigo karmin crvena (E132), željezov oksid, crveni (E172)
CellCept treatment should not be initiated in women of child bearing potential without providing a pregnancy test result to rule out unintended use in pregnancy (see section 4.6).
Liječenje lijekom CellCept ne smije se započeti kod žena reproduktivne dobi bez predočenja nalaza testa na trudnoću kako bi se isključila mogućnost nehotične primjene u trudnoći (vidjeti dio 4.6)
Cells contain two copies of the CFTR gene; Orkambi is used in patients in whom both copies are affected by the F508del mutation.
Stanice sadrže dvije kopije gena CFTR; Orkambi se primjenjuje u bolesnika u kojih su obje kopije zahvaćene mutacijom F508del.
cells/mm3 (S.E.M.d)
stanica/mm3 (S.E.M.d)
Cellular DNA polymerase γ is also sensitive to inhibition by stavudine triphosphate, while cellular polymerases α and β are inhibited at concentrations 4,000-fold and 40-fold higher, respectively, than that needed to inhibit HIV reverse transcriptase.
Stanična DNA- polimeraza γ također je osjetljiva na inhibiciju stavudin trifosfatom, dok su stanične polimeraze α i β inhibirane tek pri koncentracijama koje su 4000 puta, odnosno 40 puta više od onih koje su potrebne za inhibiciju reverzibilne transkriptaze HIV-a.
Cellular uptake does not require receptors, binding proteins or metabolic processes and does not occur by pinocytosis.
Unos u stanicu ne zahtijeva receptore, vezne proteine ili metaboličke procese te se ne događa putem pinocitoze.
Cellular uptake of talimogene laherparepvec occurs through HSV-1 receptors on tumours and non- tumour cells following local injection into tumours.
Unos virusa talimogene laherparepvec u stanicu odvija se putem HSV-1 receptora na tumorskim i ne- tumorskim stanicama nakon lokalnog injiciranja u tumore.
Cellulitis,
celulitis,
Cellulitis, Oral herpes
Celulitis, Oralni herpes
Cellulitis, Pneumonia, Oral herpes simplex, Herpes zoster
celulitis, pneumonija, oralni herpes simplex, herpes zoster
Cellulitis1 Ear infection
Celulitis1 Infekcija uha
Cellulitisd
celulitisd
Cellulose microcrystalline Croscarmellose sodium Hydroxypropylcellulose Lactose monohydrate Magnesium stearate Polysorbate 80
celuloza, mikrokristalična karmelozanatrij, umrežena hidroksipropilceluloza laktoza hidrat magnezijev stearat polisorbat 80
Cellulose microcrystalline Crospovidone
celuloza, mikrokristalična krospovidon
Cellulose microcrystalline Crospovidone Hypromellose Magnesium stearate
celuloza, mikrokristalična krospovidon
cellulose microcrystalline crospovidone hypromellose magnesium stearate lactose monohydrate sodium laurilsulfate
celuloza, mikrokristalična krospovidon hipromeloza magnezijev stearat laktoza hidrat natrijev laurilsulfat
Cellulose microcrystalline Crospovidone Type A Silica, colloidal anhydrous Magnesium stearate
celuloza, mikrokristalična krospovidon tip A silicijev dioksid, koloidni, bezvodni magnezijev stearat
Cellulose microcrystalline Silica colloidal anhydrous
celuloza, mikrokristalična silicijev dioksid, koloidni, bezvodni
Cellulose, microcrystalline (E460) Calcium hydrogen phosphate, anhydrous Maize starch
celuloza, mikrokristalinična (E460) kalcijev hidrogenfosfat, bezvodni kukuruzni škrob
Cellulose, microcrystalline (E460) Calcium hydrogen phosphate, anhydrous Maize starch
celuloza, mikrokristalična (E460) kalcijev hidrogenfosfat, bezvodni kukuruzni škrob
Cellulose, microcrystalline Colloidal anhydrous silica Crospovidone (type A) Macrogol 6000 Hydrogenated castor oil
celuloza, mikrokristalična silicijev dioksid, koloidni, bezvodni krospovidon (tip A)
Cellulose, microcrystalline Colloidal anhydrous silica Crospovidone (type A) Macrogol 6000 Hydrogenated castor oil
Koloidni bezvodni silicijev dioksidkrospovidon (tip A) makrogol 6000 ricinusovo ulje, hidrogenirano
Cellulose, microcrystalline Croscarmellose sodium Magnesium stearate
celuloza, mikrokristalična karmelozanatrij, umrežena magnezijev stearat
Cellulose, microcrystalline Crospovidone
celuloza, mikrokristalična krospovidon
Cellulose, microcrystalline Maize starch
celuloza, mikrokristalična kukuruzni škrob
Cellulose, microcrystalline Maize starch Croscarmellose sodium Hypromellose
celuloza, mikrokristalična kukuruzni škrob karmelozanatrij, umrežena hipromeloza
Cellulose, microcrystalline Mannitol
celuloza, mikrokristalična manitol
Cellulose, microcrystalline Povidone
celuloza, mikrokristalična povidon
Cellulose, microcrystalline Povidone (K-30) Crospovidone
Celuloza, mikrokristalinična Povidon (K-30) Krospovidon
Cellulose, microcrystalline Silica, colloidal anhydrous Povidone
celuloza, mikrokristalična
Cellulose, microcrystalline Sodium laurilsulfate Hydrogenated vegetable oil
celuloza, mikrokristalična natrijev laurilsulfat hidrogenirano biljno ulje
CELSENTRI 150 mg and 300 mg film-coated tablets are supplied in bottles of 180 tablets or in blister packs of 30, 60, 90 film-coated tablets and multipacks containing 180 (2 packs of 90) film-coated tablets.
CELSENTRI 150 mg i 300 mg filmom obložene tablete dostupne su u bočicama od 180 tableta ili u blisterima od 30, 60, 90 filmom obloženih tableta i višestrukom pakiranju koji sadrži 180 (2 pakiranja od 90) filmom obloženih tableta.
CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets maraviroc
CELSENTRI 150 mg filmom obložene tablete CELSENTRI 300 mg filmom obložene tablete maravirok
CELSENTRI 150 mg film-coated tablets maraviroc
CELSENTRI 150 mg filmom obložene tablete maravirok
CELSENTRI 150 mg film-coated tablets.
CELSENTRI 150 mg filmom obložene tablete
Celsentri 300 mg film-coated tablets maraviroc
Celsentri 300 mg filmom obložene tablete maravirok
CELSENTRI 300 mg film-coated tablets.
CELSENTRI 300 mg filmom obložene tablete
CELSENTRI 300 mg twice daily and buprenorphine can be co-administered without dose adjustment.
CELSENTRI 300 2x dnevno i buprenorfin se mogu istodobno primijeniti bez prilagodbe doze.
CELSENTRI 300 mg twice daily and methadone can be co-administered without dose adjustment.
CELSENTRI 300 2x dnevno i metadon se mogu istodobno primijeniti bez prilagodbe doze.
CELSENTRI 300 mg twice daily and NRTIs can be co-administered without dose adjustment.
CELSENTRI 300 mg 2x dnevno i NRTI mogu se primjenjivati istodobno bez prilagođavanja doze.
CELSENTRI 300 mg twice daily and pegylated interferon or ribavirin can be co-administered without dose adjustment.
Moguće je istodobno primijeniti CELSENTRI 300 2x dnevno i pegilirani interferon ili ribavirin bez prilagodbe doze.
CELSENTRI 300 mg twice daily and statins can be co-administered without dose adjustment.
CELSENTRI 300 2x dnevno i statini se mogu istodobno primijeniti bez prilagođavanja doze.
CELSENTRI can be taken with or without food.
CELSENTRI se može uzimati sa i bez hrane.
CELSENTRI can be taken with or without food.
CELSENTRI se može uzimati sa ili bez hrane.
CELSENTRI dose should be decreased to 150 mg twice daily when co-administered with cobicistat containing regimen.
Kada se primjenjuje istodobno s režimom koji sadrži kobicistat, dozu lijeka CELSENTRI treba smanjiti na 150 mg dvaput na dan.
CELSENTRI film-coated tablets are blue coloured with “MVC 150” or “MVC 300”.
CELSENTRI filmom obložene tablete su plave s oznakom „MVC 150“ ili „MVC 300“.
CELSENTRI has only been used in limited numbers of patients 65 years or older.
CELSENTRI se primjenjivao samo kod malog broja bolesnika od 65 godina ili starijih.
CELSENTRI is used to treat Human Immunodeficiency Virus type-1 (HIV-1) in adults.
CELSENTRI se koristi za liječenje infekcije virusom humane imunodeficijencije tipa 1 (HIV-1) u odraslih.
CELSENTRI may cause dizziness.
CELSENTRI može uzrokovati omaglicu.
CELSENTRI must be taken in combination with other medicines used to treat HIV.
CELSENTRI morate primjenjivati u kombinaciji s drugim lijekovima za liječenje HIV-a.
CELSENTRI should be used with caution in patients with severe renal impairment (CLcr <30 mL/min) who are receiving potent CYP3A4 inhibitors (see sections 4.4 and 5.2).
CELSENTRI treba primjenjivati s oprezom u bolesnika s teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min) koji uzimaju snažne inhibitore CYP3A4 (vidjeti dijelove 4.4 i 5.2).
CELSENTRI, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable (see section 4.2).
CELSENTRI je u kombinaciji s drugim antiretrovirusnim lijekovima indiciran u liječenju prethodno liječenih odraslih bolesnika, kod kojih je kao uzročnik bolesti utvrđen samo CCR5-tropni HIV-1 (vidjeti dio 4.2).
Celvapan influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated)
Celvapan cjepivo protiv influence (H1N1)v (cijeli virion, iz Vero stanica, inaktivirano)
Celvapan is a clear to opalescent, translucent liquid.
Celvapan je bistra do opalescentna, prozirna tekućina.
Celvapan is a vaccine to prevent influenza (flu) caused by A(H1N1)v 2009 virus
Celvapan je cjepivo za sprečavanje influence (gripe) prouzročene virusom A(H1N1)v 2009.
Celvapan is given according to official recommendations.
Celvapan se primjenjuje sukladno službenim preporukama.
Celvapan is given by injection into the muscle of the shoulder or thigh, as two doses at least three weeks apart.
Celvapan se primjenjuje injekcijom u mišić ramena ili bedra, kao dvije doze u razmaku od najmanje tri tjedna.
Celvapan should be used in accordance with Official Guidance
Celvapan se treba koristiti u skladu sa službenim preporukama.
Celvapan suspension for injection
Celvapan suspenzija za injekciju
Cen
Cenzur.
Censor indicated by vertical bar ׀
Cenzor indiciran vertikalnom linijom ׀
Censored
cenzurirani
Censored Censored
Cenzurirano  Cenzurirano
Censored Censored
Cenzurirano Cenzurirano
Censored for NPT
Cenzurirano za terapiju izvan protokola
Censored, n (%)
cenzurirani, n (%)
Censoring times
Vrijeme cenzuriranja
Censoring Times Everolimus (n/N = 155/277) Placebo (n/N = 111/139)
Vrijeme cenzuriranja Everolimus (n/N = 155/277) Placebo (n/N = 111/139)
Central and peripheral demyelinating events have been seen rarely and very rarely, respectively, with etanercept use.
Tijekom primjene etanercepta rijetko su viđeni slučajevi demijelinizacije u središnjem živčanom sustavu, dok su slučajevi demijelinizacije perifernog živčanog sustava opaženi vrlo rijetko.
Central nervous symptoms such as vertigo, walking instability and hemi-paresis have been observed with accidental eslicarbazepine acetate overdose.
Centralni neurološki simptomi kao što su vrtoglavica, nestabilnost hoda i hemipareza primjećene su kod slučajnog predoziranja eslikarbazepinacetatom .
Central nervous symptoms such as vertigo, walking instability and hemi-paresis have been observed with accidental eslicarbazepine acetate overdose.
Centralni neurološki simptomi kao što su vrtoglavica, nestabilnost hoda i hemipareza primjećene su kod slučajnog predoziranja eslikarbazepinacetatom.
CENTRAL NERVOUS SYSTEM (CNS) LYMPHOMA
LIMFOM SREDIŠNJEG ŽIVČANOG SUSTAVA (CNS)
Central nervous system influencing medicinal products
Lijekovi koji utječu na središnji živčani sustav
Central nervous system-related adverse events associated with the use of interferon beta might influence the patient’s ability to drive or use machines (see section 4.8).
Nuspojave glede središnjeg živčanog sustava povezane s korištenjem interferona beta mogle bi utjecati na sposobnost bolesnika da upravlja vozilima i radi sa strojevima (vidjeti dio 4.8).
Central nervous system-related adverse reactions may have a minor influence on the ability to drive and use machines in susceptible patients (see section 4.8).
Nuspojave središnjeg živčanog sustava mogu imati manji utjecaj na sposobnost podložnih bolesnika na upravljanje vozila i rada sa strojevima (vidjeti dio 4.8).
Central nervous systeminfluencing medical products
Lijekovi koji utječu na središnji živčani sustav
Central to the diagnosis are the presence of an underlying neurological condition known to cause PBA, and confirmation that the episodes of emotional expression do not reflect the patient's emotional state or mood.
Za dijagnozu je bitna prisutnost temeljne neurološke bolesti za koju je poznato da može uzrokovati pojavu pseudobulbarnog afekta, te potvrda da su epizode emocionalne ekspresije u raskoraku ili nerazmjeru s bolesnikovim emocionalnim stanjem ili raspoloženjem.
centre
prema centru
Cephalexin
Cefaleksin
Ceplene 0.5 mg/0.5 mL solution for injection
Ceplene 0,5 mg/0,5 mL otopina za injekciju
Ceplene 0.5 mg/0.5 mL solution for injection
Ceplene 0,5 mg/0,5 mL otopina za injekciju histamindiklorid
Ceplene 0.5 mg/0.5 mL solution for injection Histamine dihydrochloride
Ceplene 0,5 mg/0,5 mL otopina za injekciju histamindiklorid
Ceplene and interleukin-2 are given for 10 cycles.
Ceplene i interleukin-2 primjenjuju se u 10 ciklusa.
Ceplene and low dose IL-2 have been investigated in other clinical studies at different doses (1.0 mg histamine dihydrochloride twice a day) and with different dose regimens of low-dose IL-2 and interferon-alfa.
Ceplene i niska doza IL-2 istraživani su i u drugim kliničkim ispitivanjima pri različitim dozama (1,0 mg histamindiklorida dvaput na dan) i pri različitim režimima niske doze IL-2 i interferona-alfa.
Ceplene has been authorised under ‘exceptional circumstances’.
Ceplene je odobren u „iznimnim okolnostima”.
Ceplene has minor or moderate influence on the ability to drive and use machines.
Ceplene ima malen ili umjeren utjecaj na sposobnost upravljanja vozilima i rada sa strojevima.
Ceplene histamine dihydrochloride
Ceplene histamine dihidroklorid
Ceplene in conjunction with IL-2 must not be used during breast-feeding.
Tijekom dojenja, Ceplene se ne smije primjenjivati u kombinaciji s IL-2.
Ceplene is a solution for injection that contains the active substance histamine dihydrochloride (0.5 mg/0.5 ml).
Ceplene je otopina za injekciju koja sadrži djelatnu tvar histamine dihidroklorid (0,5 mg/0,5 ml).
Ceplene is for subcutaneous use only.
Ceplene se primjenjuje samo supkutano.
Ceplene is injected subcutaneously so that absorption from the gastrointestinal tract is not influenced by food and drink.
Ceplene se ubrizgava potkožno pa na apsorpciju iz probavnog sustava ne utječu hrana ili piće.
Ceplene is used in combination with interleukin-2 (an anticancer medicine) as maintenance treatment in adults with acute myeloid leukaemia (AML), a type of cancer affecting the white blood cells.
Ceplene se koristi u kombinaciji s lijekom interleukin-2 (anticitostatikom) kao terapija održavanja indiciran u odraslih bolesnika s akutnom mijeloičnom leukemijom (AML), tipom raka koji obuhvaća bijele krvne stanice.
Ceplene is used, together with IL-2, to treat a particular type of leukaemia called acute myeloid leukaemia (AML) which is a cancer of blood forming cells in the bone marrow.
Ceplene se, zajedno s IL-2, koristi za liječenje određenog tipa leukemije pod nazivom akutna mijeloična leukemija (AML), raka stanica u koštanoj srži koje stvaraju krv.
Ceplene must be injected 1 to 3 minutes later.
Ceplene se mora ubrizgavati 1 do 3 minute kasnije.
Ceplene must be injected slowly in the layer of tissue just under the skin (subcutaneously), over a period of approximately 5 to 15 minutes.
Ceplene se mora ubrizgavati polagano, u sloj tkiva odmah ispod kože (potkožno), tijekom razdoblja od približno 5 do 15 minuta.
Ceplene must not be used in patients who have severe heart problems or in women who are pregnant or breast-feeding.
Ceplene se ne smije koristiti u bolesnika koji imaju ozbiljne srčane problem ili u žena koje su trudne ili doje.
Ceplene should be given under the supervision of a doctor who has experience in the treatment of AML.
Ceplene treba primjenjivati pod nadzorom liječnika s iskustvom u liječenju AML-a.
Ceplene was given in combination with interleukin-2 and compared with no treatment.
Ceplene je primijenjen u kombinaciji s lijekom interleukin-2 i uspoređen je sa slučajevima kada nije primijenjena terapija.
Ceplene with food, drink and alcohol
Ceplene s hranom, pićem i alkoholom
CEPROTIN has no influence on the ability to drive and use machines.
CEPROTIN ne utječe na sposobnost upravljanja vozilima i rada na strojevima.
CEPROTIN has no influence on your ability to drive or to operate machines.
CEPROTIN ne utječe na Vašu sposobnost upravljanja vozilima ili rada na strojevima.
Cerdelga (n=20) a
Cerdelga (n=20)a
Cerdelga 84 mg capsules, hard
Cerdelga 84 mg kapsule, tvrde
Cerdelga 84 mg capsules, hard eliglustat
Cerdelga 84 mg kapsule, tvrde eliglustat
Cerdelga contains the active substance eliglustat which decreases the production of glucosylceramide, thereby preventing its build- up.
Cerdelga sadrži djelatnu tvar eliglustat koja smanjuje stvaranje glukozilceramida i tako sprječava njegovo nakupljanje.
Cerdelga has been shown to be effective in treating Gaucher disease in two main studies.
Utvrđeno je da je lijek Cerdelga djelotvoran u liječenju Gaucherove bolesti u dva glavna ispitivanja.